{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:09:24Z","timestamp":1790813364703,"version":"4.1.0"},"reference-count":93,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T00:00:00Z","timestamp":1603065600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["2016\/23\/D\/NZ7\/03636"],"award-info":[{"award-number":["2016\/23\/D\/NZ7\/03636"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>AA3266 is a hybrid compound consisting of opioid receptor agonist and neurokinin-1 receptor (NK1R) antagonist pharmacophores. It was designed with the desire to have an analgesic molecule with improved properties and auxiliary anticancer activity. Previously, the compound was found to exhibit high affinity for \u03bc- and \u03b4-opioid receptors, while moderate binding to NK1R. In the presented contribution, we report on a deeper investigation of this hybrid. In vivo, we have established that AA3266 has potent antinociceptive activity in acute pain model, comparable to that of morphine. Desirably, with prolonged administration, our hybrid induces less tolerance than morphine does. AA3266, contrary to morphine, does not cause development of constipation, which is one of the main undesirable effects of opioid use. In vitro, we have confirmed relatively strong cytotoxic activity on a few selected cancer cell lines, similar to or greater than that of a reference NK1R antagonist, aprepitant. Importantly, our compound affects normal cells to smaller extent what makes our compound more selective against cancer cells. In silico methods, including molecular docking, molecular dynamics simulations and fragment molecular orbital calculations, have been used to investigate the interactions of AA3266 with MOR and NK1R. Insights from these will guide structural optimization of opioid\/antitachykinin hybrid compounds.<\/jats:p>","DOI":"10.3390\/ijms21207738","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T20:44:41Z","timestamp":1603140281000},"page":"7738","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["In Vivo, In Vitro and In Silico Studies of the Hybrid Compound AA3266, an Opioid Agonist\/NK1R Antagonist with Selective Cytotoxicity"],"prefix":"10.3390","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0837-7171","authenticated-orcid":false,"given":"Joanna","family":"Matali\u0144ska","sequence":"first","affiliation":[{"name":"Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8364-7955","authenticated-orcid":false,"given":"Piotr F. J.","family":"Lipi\u0144ski","sequence":"additional","affiliation":[{"name":"Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kosson","sequence":"additional","affiliation":[{"name":"Toxicology Research Laboratory, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Kosi\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7446-2396","authenticated-orcid":false,"given":"Aleksandra","family":"Misicka","sequence":"additional","affiliation":[{"name":"Department of Neuropeptides, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawi\u0144skiego 5, 02-106 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,10,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/bja\/aet123","article-title":"Chronic pain epidemiology and its clinical relevance","volume":"111","author":"Torrance","year":"2013","journal-title":"Br. J. Anaesth."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/S0140-6736(11)60402-9","article-title":"Treatment of chronic non-cancer pain","volume":"377","author":"Turk","year":"2011","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1526-5900(03)00556-X","article-title":"Management of opioid side effects in cancer-related and chronic noncancer pain: A systematic review","volume":"4","author":"McNicol","year":"2003","journal-title":"J. Pain"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejmech.2015.11.028","article-title":"Multitarget opioid ligands in pain relief: New players in an old game","volume":"108","author":"Turnaturi","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.4155\/fmc.15.156","article-title":"The design of multitarget ligands for chronic and neuropathic pain","volume":"7","author":"Dvoracsko","year":"2015","journal-title":"Future Med. Chem."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"7848","DOI":"10.1021\/jm200894e","article-title":"Superpotent [Dmt1]Dermorphin Tetrapeptides Containing the 4-Aminotetrahydro-2-benzazepin-3-one Scaffold with Mixed \u03bc\/\u03b4 Opioid Receptor Agonistic Properties","volume":"54","author":"Vandormael","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1021\/jm100982d","article-title":"Development of Potent \u03bc and \u03b4 Opioid Agonists with High Lipophilicity","volume":"54","author":"Lee","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1021\/cb200263q","article-title":"Development and In Vitro Characterization of a Novel Bifunctional \u03bc-Agonist\/\u03b4-Antagonist Opioid Tetrapeptide","volume":"6","author":"Purington","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1021\/cn900025j","article-title":"Evolution of the Bifunctional Lead \u03bc Agonist\/\u03b4 Antagonist Containing the 2\u2032,6\u2032-Dimethyl-l-tyrosine\u22121,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acid (Dmt\u2212Tic) Opioid Pharmacophore","volume":"1","author":"Balboni","year":"2010","journal-title":"ACS Chem. Neurosci."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/jm061268p","article-title":"Partial Retro\u2212Inverso, Retro, and Inverso Modifications of Hydrazide Linked Bifunctional Peptides for Opioid and Cholecystokinin (CCK) Receptors","volume":"50","author":"Lee","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1021\/jm050921q","article-title":"Structure\u2212Activity Relationships of Bifunctional Peptides Based on Overlapping Pharmacophores at Opioid and Cholecystokinin Receptors","volume":"49","author":"Agnes","year":"2006","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a New Opioid-Neurotensin Hybrid Peptide That Exhibits Central and Peripheral Antinociceptive Effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol. Pain"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Gonzalez, S., Dumitrascuta, M., Eiselt, E., Louis, S., Kunze, L., Blasiol, A., Vivancos, M., Previti, S., Dewolf, E., and Martin, C. (2020). Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies. J. Med. Chem.","DOI":"10.1021\/acs.jmedchem.0c01376"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"108232","DOI":"10.1016\/j.neuropharm.2020.108232","article-title":"Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain","volume":"178","author":"Piotrowska","year":"2020","journal-title":"Neuropharmacology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.9b01256","article-title":"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual \u03bc-Opioid Receptor Agonists and \u03c31 Receptor Antagonists for the Treatment of Pain","volume":"63","author":"Virgili","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"112144","DOI":"10.1016\/j.ejmech.2020.112144","article-title":"Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain","volume":"191","author":"Xiong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Dyniewicz, J., Lipi\u0144ski, P.F.J., Kosson, P., Bochy\u0144ska-Czy\u017c, M., Matali\u0144ska, J., and Misicka, A. (2020). Antinociceptive and Cytotoxic Activity of Opioid Peptides with Hydrazone and Hydrazide Moieties at the C-Terminus. Molecules, 25.","DOI":"10.3390\/molecules25153429"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ejmech.2019.05.037","article-title":"Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors","volume":"178","author":"Keresztes","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.6b01181","article-title":"Structure-Based Optimization of Multifunctional Agonists for Opioid and Neuropeptide FF Receptors with Potent Nontolerance Forming Analgesic Activities","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2018.11.007","article-title":"Neurokinin-1 receptor-based bivalent drugs in pain management: The journey to nowhere?","volume":"196","author":"Kleczkowska","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"ref_21","first-page":"195","article-title":"Substance P: Transmitter of nociception (Minireview)","volume":"34","author":"Zubrzycka","year":"2000","journal-title":"Endocr. Regul."},{"key":"ref_22","first-page":"11","article-title":"Neurokinin 1 and opioid receptors: Relationships and interactions in nervous system","volume":"1","author":"Xiao","year":"2016","journal-title":"Transl. Perioper. Pain Med."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Wtorek, K., Adamska-Bart\u0142omiejczyk, A., Piekielna-Ciesielska, J., Ferrari, F., Ruzza, C., Kluczyk, A., Piasecka-Zelga, J., Calo\u2019, G., and Janecka, A. (2019). Synthesis and Pharmacological Evaluation of Hybrids Targeting Opioid and Neurokinin Receptors. Molecules, 24.","DOI":"10.3390\/molecules24244460"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz, M., and Cove\u00f1as, R. (2020). The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. J. Clin. Med., 9.","DOI":"10.20944\/preprints202004.0224.v1"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Mu\u00f1oz, M., and Cove\u00f1as, R. (2020). The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?. Cancers, 12.","DOI":"10.3390\/cancers12092682"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/138945011795528796","article-title":"The NK-1 Receptor: A New Target in Cancer Therapy","volume":"12","author":"Munoz","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1517\/13543776.2012.697153","article-title":"NK-1 receptor antagonists as antitumor drugs: A survey of the literature from 2000 to 2011","volume":"22","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"19635","DOI":"10.1073\/pnas.1908998116","article-title":"Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload","volume":"116","author":"Ge","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.5114\/fn.2013.35956","article-title":"Opioid agonist\u2013tachykinin antagonist as a new analgesic with adjuvant anticancer properties","volume":"2","author":"Matalinska","year":"2013","journal-title":"Folia Neuropathol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/jnr.21053","article-title":"Morphine upregulates functional expression of neurokinin-1 receptor in neurons","volume":"84","author":"Wan","year":"2006","journal-title":"J. Neurosci. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.pain.2005.04.014","article-title":"Role of NK-1 neurotransmission in opioid-induced hyperalgesia","volume":"116","author":"King","year":"2005","journal-title":"Pain"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0304-3959(01)00311-6","article-title":"Mechanisms of opioid-induced pain and antinociceptive tolerance: Descending facilitation and spinal dynorphin","volume":"92","author":"Vanderah","year":"2001","journal-title":"Pain"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0024-3205(94)00494-3","article-title":"Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin","volume":"54","author":"Misterek","year":"1994","journal-title":"Life Sci."},{"key":"ref_34","first-page":"1142","article-title":"Inhibition of morphine tolerance development by a substance P-opioid peptide chimera","volume":"295","author":"Foran","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ejphar.2004.02.023","article-title":"Spinal antinociceptive effects of AA501, a novel chimeric peptide with opioid receptor agonist and tachykinin receptor antagonist moieties","volume":"488","author":"Bonney","year":"2004","journal-title":"Eur. J. Pharmacol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/j.1476-5381.2010.00824.x","article-title":"Spinal or systemic TY005, a peptidic opioid agonist\/neurokinin 1 antagonist, attenuates pain with reduced tolerance","volume":"161","author":"Yamamoto","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1124\/jpet.113.205245","article-title":"Building a Better Analgesic: Multifunctional Compounds that Address Injury-Induced Pathology to Enhance Analgesic Efficacy while Eliminating Unwanted Side Effects","volume":"347","author":"Brookshire","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1021\/jm061369n","article-title":"Design, Synthesis, and Biological Evaluation of Novel Bifunctional C-Terminal-Modified Peptides for \u03b4\/\u03bc Opioid Receptor Agonists and Neurokinin-1 Receptor Antagonists","volume":"50","author":"Yamamoto","year":"2007","journal-title":"J. Med. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/jm1016285","article-title":"Design of Novel Neurokinin 1 Receptor Antagonists Based on Conformationally Constrained Aromatic Amino Acids and Discovery of a Potent Chimeric Opioid Agonist-Neurokinin 1 Receptor Antagonist","volume":"54","author":"Ballet","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1021\/acsmedchemlett.5b00359","article-title":"Dual Alleviation of Acute and Neuropathic Pain by Fused Opioid Agonist-Neurokinin 1 Antagonist Peptidomimetics","volume":"6","author":"Betti","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.ejmech.2014.12.033","article-title":"Synthesis and biological evaluation of compact, conformationally constrained bifunctional opioid agonist\u2013neurokinin-1 antagonist peptidomimetics","volume":"92","author":"Guillemyn","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1021\/acschemneuro.7b00226","article-title":"Analgesic properties of opioid\/NK1 multitarget ligands with distinct in vitro profiles in naive and chronic constriction injury (CCI)-mice","volume":"8","author":"Starnowska","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1756-6606-5-4","article-title":"In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist-neurokinin 1 receptor antagonist chimera","volume":"5","author":"Guillemyn","year":"2012","journal-title":"Mol. Brain"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Matali\u0144ska, J., Lipi\u0144ski, P.F.J., Kotlarz, A., Kosson, P., Muchowska, A., and Dyniewicz, J. (2020). Evaluation of Receptor Affinity, Analgesic Activity and Cytotoxicity of a Hybrid Peptide, AWL3020. Int. J. Pept. Res. Ther.","DOI":"10.1007\/s10989-020-10051-5"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Matali\u0144ska, J., Swi\u0107, A., Lipi\u0144ski, P.F.J., and Misicka, A. (2020). Antiproliferative effects of [D-Pro2, D-Trp7,9]-substance P and aprepitant on several cancer cell lines and their selectivity in comparison to normal cells. Folia Neuropathol., 58, in press.","DOI":"10.5114\/fn.2020.100066"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","article-title":"The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug","volume":"28","author":"Rosso","year":"2010","journal-title":"Invest. New Drugs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s12038-015-9530-8","article-title":"The substance P\/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs","volume":"40","author":"Esteban","year":"2015","journal-title":"J. Biosci."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/labinvest.2010.92","article-title":"The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines","volume":"90","author":"Rosso","year":"2010","journal-title":"Lab. Investig."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijo.2013.2164","article-title":"Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts","volume":"44","author":"Berger","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-015-1996-6","article-title":"Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells","volume":"126","author":"Kast","year":"2016","journal-title":"J. Neurooncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","article-title":"The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer","volume":"45","author":"Carranza","year":"2014","journal-title":"Int. J. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/cmdc.201700453","article-title":"Opioid Tripeptides Hybridized with trans -1-Cinnamylpiperazine as Proliferation Inhibitors of Pancreatic Cancer Cells in Two- and Three-Dimensional in vitro Models","volume":"12","author":"Laskowska","year":"2017","journal-title":"ChemMedChem"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e12527","DOI":"10.1111\/cpr.12527","article-title":"MiR-34b\/c-5p and the neurokinin-1 receptor regulate breast cancer cell proliferation and apoptosis","volume":"52","author":"Zhang","year":"2019","journal-title":"Cell Prolif."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1007\/s11033-020-05330-9","article-title":"The role of substance P\/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K\/Akt\/NF-\u03baB signal transduction pathways","volume":"47","author":"Javid","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/DDDT.S244648","article-title":"Aprepitant Sensitizes Acute Myeloid Leukemia Cells to the Cytotoxic Effects of Cytosine Arabinoside in vitro and in vivo","volume":"14","author":"Wu","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2013.12.024","article-title":"Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo","volume":"60","author":"Berger","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.neuroscience.2013.12.027","article-title":"Evaluating the role of substance P in the growth of brain tumors","volume":"261","author":"Lewis","year":"2014","journal-title":"Neuroscience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/s41586-018-0219-7","article-title":"Structure of the \u00b5-opioid receptor\u2013Gi protein complex","volume":"558","author":"Koehl","year":"2018","journal-title":"Nature"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"7560","DOI":"10.1002\/anie.201501742","article-title":"The mechanism of ligand-induced activation or inhibition of \u03bc- and \u03ba-opioid receptors","volume":"54","author":"Yuan","year":"2015","journal-title":"Angew. Chemie Int. Ed."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0024-3205(99)00234-9","article-title":"Asp147 in the third transmembrane helix of the rat \u03bc opioid receptor forms ion-pairing with morphine and naltrexone","volume":"65","author":"Li","year":"1999","journal-title":"Life Sci."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1021\/acs.jcim.5b00280","article-title":"Activation and Allosteric Modulation of Human \u03bc Opioid Receptor in Molecular Dynamics","volume":"55","author":"Bartuzi","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.2174\/0929867323666160427123005","article-title":"Cyclic Opioid Peptides","volume":"23","author":"Remesic","year":"2016","journal-title":"Curr. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2174\/1389450111314070008","article-title":"Cyclization in Opioid Peptides","volume":"14","author":"Piekielna","year":"2013","journal-title":"Curr. Drug Targets"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41467-018-07939-8","article-title":"Crystal structures of the human neurokinin 1 receptor in complex with clinically used antagonists","volume":"10","author":"Ehrenmann","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Tymecka, D., Lipi\u0144ski, P.F.J., Kosson, P., and Misicka, A. (2020). \u03b22-Homo-Amino Acid Scan of \u00b5-Selective Opioid Tetrapeptide TAPP. Molecules, 25.","DOI":"10.3390\/molecules25102461"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature14886","article-title":"Structural insights into \u00b5-opioid receptor activation","volume":"524","author":"Huang","year":"2015","journal-title":"Nature"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Lipi\u0144ski, P.F.J., Kosson, P., Matali\u0144ska, J., Roszkowski, P., Czarnocki, Z., Jaro\u0144czyk, M., Misicka, A., Dobrowolski, J., and Sadlej, J. (2019). Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis. Molecules, 24.","DOI":"10.3390\/molecules24040740"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1002\/cmdc.202000248","article-title":"Pharmacological Profile and Molecular Modeling of Cyclic Opioid Analogues Incorporating Various Phenylalanine Derivatives","volume":"15","author":"Kluczyk","year":"2020","journal-title":"ChemMedChem"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Dumitrascuta, M., Bermudez, M., Ballet, S., Wolber, G., and Spetea, M. (2020). Mechanistic Understanding of Peptide Analogues, DALDA, [Dmt1]DALDA, and KGOP01, Binding to the Mu Opioid Receptor. Molecules, 25.","DOI":"10.3390\/molecules25092087"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"13264","DOI":"10.1073\/pnas.1812717115","article-title":"Crystal structure of the human NK 1 tachykinin receptor","volume":"115","author":"Yin","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/s41467-019-08568-5","article-title":"Human substance P receptor binding mode of the antagonist drug aprepitant by NMR and crystallography","volume":"10","author":"Chen","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4296","DOI":"10.1021\/jm0109558","article-title":"An Orally Active, Water-Soluble Neurokinin-1 Receptor Antagonist Suitable for Both Intravenous and Oral Clinical Administration","volume":"44","author":"Harrison","year":"2001","journal-title":"J. Med. Chem."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Halik, P.K., Lipi\u0144ski, P.F.J., Matali\u0144ska, J., Ko\u017ami\u0144ski, P., Misicka, A., and Gniazdowska, E. (2020). Radiochemical Synthesis and Evaluation of Novel Radioconjugates of Neurokinin 1 Receptor Antagonist Aprepitant Dedicated for NK1R-Positive Tumors. Molecules, 25.","DOI":"10.3390\/molecules25163756"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nsmb.2965","article-title":"Structural basis for bifunctional peptide recognition at human \u03b4-opioid receptor","volume":"22","author":"Fenalti","year":"2015","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1073\/pnas.1510117112","article-title":"NMR structure and dynamics of the agonist dynorphin peptide bound to the human kappa opioid receptor","volume":"112","author":"White","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Vo, Q.N., Mahinthichaichan, P., Shen, J., and Ellis, C.R. (2020). How \u03bc-Opioid Receptor Recognizes Fentanyl. bioRxiv Prepr. Serv. Biol.","DOI":"10.21203\/rs.3.rs-67888\/v1"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"18045","DOI":"10.1074\/jbc.M113.527085","article-title":"Mapping substance P binding sites on the neurokinin-1 receptor using genetic incorporation of a photoreactive amino acid","volume":"289","author":"Park","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_79","unstructured":"Lipkowski, A. (2014). Method of Producing a Novel Opioid Peptide. (US8877891B2)."},{"key":"ref_80","first-page":"190","article-title":"Analgesic effects of intraventricular morphine and enkephalins in nondependent and morphine-dependent rats","volume":"222","author":"Brady","year":"1982","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_81","unstructured":"GraphPad Prism 8 Version 8.3.1 San Diego, C.A."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"D440","DOI":"10.1093\/nar\/gkx1109","article-title":"GPCRdb in 2018: Adding GPCR structure models and ligands","volume":"46","author":"Munk","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/bioinformatics\/btk023","article-title":"OPM: Orientations of proteins in membranes database","volume":"22","author":"Lomize","year":"2006","journal-title":"Bioinformatics"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM Simulations Using the CHARMM36 Additive Force Field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/jcc.21367","article-title":"CHARMM general force field: A force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields","volume":"31","author":"Vanommeslaeghe","year":"2009","journal-title":"J. Comput. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"ref_87","unstructured":"Schr\u00f6dinger LLC (2020, September 30). The PyMOL Molecular Graphics System. Available online: sourceforge.net\/p\/pymol\/code\/HEAD\/tree\/trunk\/pymol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.2174\/156802612804910269","article-title":"GAMESS As a Free Quantum-Mechanical Platform for Drug Research","volume":"12","author":"Alexeev","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"154102","DOI":"10.1063\/5.0005188","article-title":"Recent developments in the general atomic and molecular electronic structure system","volume":"152","author":"Barca","year":"2020","journal-title":"J. Chem. Phys."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"6832","DOI":"10.1063\/1.1687334","article-title":"The importance of three-body terms in the fragment molecular orbital method","volume":"120","author":"Fedorov","year":"2004","journal-title":"J. Chem. Phys."},{"key":"ref_91","unstructured":"Suenaga, M. (2020, September 30). FACIO Version 22.1.1. Available online: http:\/\/zzzfelis.sakura.ne.jp\/."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/jcc.20496","article-title":"Pair interaction energy decomposition analysis","volume":"28","author":"Fedorov","year":"2007","journal-title":"J. Comput. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s00894-019-3995-6","article-title":"Recognition of repulsive and attractive regions of selected serotonin receptor binding site using FMO-EDA approach","volume":"25","author":"Kurczab","year":"2019","journal-title":"J. Mol. Model."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7738\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:24:15Z","timestamp":1760178255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/21\/20\/7738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,19]]},"references-count":93,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2020,10]]}},"alternative-id":["ijms21207738"],"URL":"https:\/\/doi.org\/10.3390\/ijms21207738","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,19]]}}}